Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
McKesson
Johnson and Johnson
Mallinckrodt

Last Updated: August 15, 2022

Investigational Drug Information for Miravirsen


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Miravirsen?

Miravirsen is an investigational drug.

There have been 5 clinical trials for Miravirsen. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2012.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Santaris Pharma A/S and [disabled in preview].

There are fourteen US patents protecting this investigational drug and two hundred and ninety-one international patents.

Recent Clinical Trials for Miravirsen
TitleSponsorPhase
Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis CSantaris Pharma A/SPhase 2
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus InfectionSantaris Pharma A/SPhase 2
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis CSantaris Pharma A/SPhase 2

See all Miravirsen clinical trials

Clinical Trial Summary for Miravirsen

Top disease conditions for Miravirsen
Top clinical trial sponsors for Miravirsen

See all Miravirsen clinical trials

US Patents for Miravirsen

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Miravirsen See Plans and Pricing Oligonucleotide conjugates Roche Innovation Center Copenhagen A/S (Basel, CH) See Plans and Pricing
Miravirsen See Plans and Pricing Poly oligomer compound with biocleavable conjugates Hoffmann-La Roche, Inc. (Little Falls, NJ) See Plans and Pricing
Miravirsen See Plans and Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY) See Plans and Pricing
Miravirsen See Plans and Pricing Use of AAC-11 inhibitors for the treatment of viral infection INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT-PARIS 7 (Paris, FR) INSTITUT PASTEUR (Paris, FR) See Plans and Pricing
Miravirsen See Plans and Pricing Method of treating intracellular infection WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Parkville, Victoria, AU) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Miravirsen

Drugname Country Document Number Estimated Expiration Related US Patent
Miravirsen World Intellectual Property Organization (WIPO) WO2015077368 2033-11-22 See Plans and Pricing
Miravirsen Australia AU2013346767 2032-11-15 See Plans and Pricing
Miravirsen Australia AU2014211406 2032-11-15 See Plans and Pricing
Miravirsen Australia AU2014300981 2032-11-15 See Plans and Pricing
Miravirsen Australia AU2019202288 2032-11-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
McKesson
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.